Femasys (NASDAQ:FEMY) Earns Buy Rating from HC Wainwright

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $15.00 price objective on the stock.

Femasys Stock Performance

Shares of Femasys stock opened at $1.29 on Friday. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.86. The company has a market cap of $29.54 million, a PE ratio of -1.59 and a beta of -2.85. The company has a 50 day moving average of $1.41 and a 200-day moving average of $1.23. Femasys has a 1-year low of $0.86 and a 1-year high of $1.84.

Femasys (NASDAQ:FEMY) last released its earnings results on Thursday, March 27th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.02. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%. The firm had revenue of $0.58 million during the quarter, compared to analysts’ expectations of $1.66 million. As a group, equities research analysts forecast that Femasys will post -0.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Femasys

Hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new position in Femasys during the 4th quarter worth approximately $25,000. Jane Street Group LLC acquired a new position in shares of Femasys during the fourth quarter worth $30,000. XTX Topco Ltd increased its holdings in shares of Femasys by 123.9% during the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after buying an additional 18,004 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Femasys in the 4th quarter valued at $45,000. Finally, Northern Trust Corp boosted its holdings in shares of Femasys by 42.6% during the 4th quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock valued at $139,000 after acquiring an additional 37,675 shares in the last quarter. 65.27% of the stock is currently owned by institutional investors and hedge funds.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.